MX2020006799A - Derivados de oxi-fluoropiperidina como inhibidor de cinasa. - Google Patents

Derivados de oxi-fluoropiperidina como inhibidor de cinasa.

Info

Publication number
MX2020006799A
MX2020006799A MX2020006799A MX2020006799A MX2020006799A MX 2020006799 A MX2020006799 A MX 2020006799A MX 2020006799 A MX2020006799 A MX 2020006799A MX 2020006799 A MX2020006799 A MX 2020006799A MX 2020006799 A MX2020006799 A MX 2020006799A
Authority
MX
Mexico
Prior art keywords
oxy
kinase inhibitor
fluoropiperidine
derivative
fluoropiperidine derivative
Prior art date
Application number
MX2020006799A
Other languages
English (en)
Inventor
In Woo Kim
Sun Ah Jun
Jun Hee Lee
Nam Youn Kim
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MX2020006799A publication Critical patent/MX2020006799A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

La presente invención se refiere a un compuesto representado por la siguiente Fórmula Química 1, o una sal farmacéuticamente aceptable del mismo, y el compuesto de acuerdo con la presente invención puede usarse de manera útil para la prevención o tratamiento de enfermedades que se asocian con acciones inhibitorias de cinasa.
MX2020006799A 2017-12-28 2018-12-28 Derivados de oxi-fluoropiperidina como inhibidor de cinasa. MX2020006799A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170183061 2017-12-28
PCT/KR2018/016814 WO2019132562A1 (ko) 2017-12-28 2018-12-28 카이네이즈 저해제로서의 옥시-플루오로피페리딘 유도체

Publications (1)

Publication Number Publication Date
MX2020006799A true MX2020006799A (es) 2020-09-03

Family

ID=67067864

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006799A MX2020006799A (es) 2017-12-28 2018-12-28 Derivados de oxi-fluoropiperidina como inhibidor de cinasa.

Country Status (32)

Country Link
US (1) US11339167B2 (es)
EP (1) EP3733673B1 (es)
JP (1) JP6995428B2 (es)
KR (2) KR102318929B1 (es)
CN (1) CN111527091B (es)
AU (1) AU2018394997B2 (es)
BR (1) BR112020013141B1 (es)
CA (1) CA3084962C (es)
CL (1) CL2020001752A1 (es)
CO (1) CO2020007162A2 (es)
DO (1) DOP2020000112A (es)
EC (1) ECSP20035590A (es)
ES (1) ES2922633T3 (es)
HR (1) HRP20221043T1 (es)
HU (1) HUE059580T2 (es)
IL (1) IL275207B (es)
LT (1) LT3733673T (es)
MA (1) MA51431B1 (es)
MX (1) MX2020006799A (es)
MY (1) MY194468A (es)
NZ (1) NZ764644A (es)
PE (1) PE20201146A1 (es)
PH (1) PH12020551013A1 (es)
PL (1) PL3733673T3 (es)
PT (1) PT3733673T (es)
RS (1) RS63515B1 (es)
RU (1) RU2758370C1 (es)
SA (1) SA520412335B1 (es)
SG (1) SG11202004917UA (es)
SI (1) SI3733673T1 (es)
TN (1) TN2020000082A1 (es)
WO (1) WO2019132562A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002265A2 (pt) 2017-08-01 2020-07-28 Theravance Biopharma R&D Ip, Llc compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
MX2020006799A (es) * 2017-12-28 2020-09-03 Daewoong Pharmaceutical Co Ltd Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
EP3914348A1 (en) 2019-01-23 2021-12-01 Theravance Biopharma R&D IP, LLC Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
CN115023428A (zh) * 2020-01-21 2022-09-06 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2021147953A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
WO2022062601A1 (zh) * 2020-09-22 2022-03-31 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
CA2723185A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
ES2659725T3 (es) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
AU2011269989B2 (en) 2010-06-23 2014-12-11 Hanmi Science Co., Ltd. Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
PE20141228A1 (es) * 2011-09-22 2014-10-01 Pfizer Derivados de pirrolopirimidina y purina
CA2881275C (en) 2012-08-06 2020-10-20 Acea Biosciences Inc. Pyrrolopyrimidine compounds as inhibitors of protein kinases
AR094494A1 (es) 2013-01-16 2015-08-05 Signal Pharm Llc Pirrolopirimidinas sustituidas, sus composiciones, y sus métodos de tratamiento
EP2964647A1 (en) 2013-03-05 2016-01-13 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
AU2014323777C1 (en) * 2013-09-18 2018-04-26 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
SI3318565T1 (sl) * 2013-12-05 2021-07-30 Pfizer Inc. Pirolo(2,3-D)pirimidinil, pirolo(2,3-B)pirazinil in pirolo(2,3-D)piridinil akrilamidi
CN105777756B (zh) 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN105732637B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
US10023579B2 (en) 2015-12-16 2018-07-17 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
MX2021009378A (es) 2016-06-30 2022-06-29 Daewoong Pharmaceutical Co Ltd Derivados de pirazolopirimidina como inhibidor de cinasa.
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
MX2020006799A (es) * 2017-12-28 2020-09-03 Daewoong Pharmaceutical Co Ltd Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체

Also Published As

Publication number Publication date
CA3084962A1 (en) 2019-07-04
RU2758370C1 (ru) 2021-10-28
JP2021506818A (ja) 2021-02-22
CN111527091A (zh) 2020-08-11
EP3733673A4 (en) 2021-06-09
BR112020013141A2 (pt) 2021-02-23
SG11202004917UA (en) 2020-06-29
MY194468A (en) 2022-11-30
JP6995428B2 (ja) 2022-01-14
US20200308177A1 (en) 2020-10-01
NZ764644A (en) 2023-06-30
IL275207A (en) 2020-07-30
MA51431B1 (fr) 2022-08-31
EP3733673B1 (en) 2022-06-29
KR102318929B1 (ko) 2021-10-28
US11339167B2 (en) 2022-05-24
PT3733673T (pt) 2022-07-18
DOP2020000112A (es) 2020-08-31
KR20210062618A (ko) 2021-05-31
ECSP20035590A (es) 2020-07-31
HRP20221043T1 (hr) 2022-11-11
KR20190080803A (ko) 2019-07-08
KR102592083B1 (ko) 2023-10-20
TN2020000082A1 (en) 2022-01-06
BR112020013141B1 (pt) 2022-03-15
SI3733673T1 (sl) 2022-09-30
PL3733673T3 (pl) 2022-09-26
RS63515B1 (sr) 2022-09-30
CO2020007162A2 (es) 2020-06-19
IL275207B (en) 2022-09-01
EP3733673A1 (en) 2020-11-04
PH12020551013A1 (en) 2021-08-16
PE20201146A1 (es) 2020-10-26
SA520412335B1 (ar) 2022-09-19
AU2018394997B2 (en) 2021-02-04
CA3084962C (en) 2022-08-09
MA51431A (fr) 2021-04-07
LT3733673T (lt) 2022-08-10
CL2020001752A1 (es) 2020-11-27
WO2019132562A1 (ko) 2019-07-04
HUE059580T2 (hu) 2022-11-28
CN111527091B (zh) 2023-03-28
ES2922633T3 (es) 2022-09-19
AU2018394997A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
NZ765152A (en) Amino-methyl piperidine derivative as kinase inhibitor
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12019500480A1 (en) Pyridine compound
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
WO2018044767A3 (en) Aminopyrimidines as alk inhibitors
MY193239A (en) Novel b-lactamase inhibitors
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
PH12018500999A1 (en) Sodium channel blocker
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MX2020004972A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia.